Education
About Us
Working with TipRanks
Follow Us
Sanofi (SNY)
NASDAQ:SNY
SNY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$45.22 - $60.12
Previous CloseN/A
Volume824.98K
Average Volume (3M)3.08M
Market Cap
$125.03B
Enterprise Value$132.39B
Total Cash (Recent Filing)€6.38B
Total Debt (Recent Filing)€14.53B
Price to Earnings (P/E)21.4
Beta0.42
Next Earnings
Apr 24, 2025EPS Estimate
0.92Next Dividend Ex-Date
May 09, 2025Dividend Yield2.79%
Share Statistics
EPS (TTM)0.68
Shares Outstanding2,467,132,000
10 Day Avg. Volume3,221,023
30 Day Avg. Volume3,075,428
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.97
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$64.00Price Target Upside20.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Financial StabilitySanofi has a healthy balance sheet with strong operating cash flow.
Pipeline And Product ExpansionSanofi holds a diverse pipeline and is expected to launch or expand indications for over 10 drugs in FY25.
Product ApprovalQfitlia was approved by the FDA for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B.
Bears Say
CompetitionThere is risk of Dupixent’s market share being diminished if competitors' alternatives are successfully developed and launched.
Safety ConcernsQfitlia requires liver tests and monitoring for signs and symptoms of acute and recurrent gallbladder disease, indicating potential safety concerns.
---
Ownership Overview
―
Insiders
3.83% Mutual Funds
0.05% Other Institutional Investors
95.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SNY FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was $45.22 and its highest was $60.12 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $125.03B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Apr 24, 2025 which is yesterday.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Apr 24, 2025. The company reported $0.785 earnings per share for the quarter, missing the consensus estimate of $0.929 by -$0.144.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of $1.609 which represents an annual dividend yield of 2.79%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 0.92.
How many shares outstanding does Sanofi have?
Sanofi has 2,467,132,000 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of $0.785 in its last earnings report, missing expectations of $0.929. Following the earnings report the stock price went up 0.981%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in SNY
---
Sanofi Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$64.00 (20.71% Upside)
$64.00 (20.71% Upside)
Blogger Sentiment
Bullish
SNY Sentiment 92%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.29%
12-Months-Change
Fundamentals
Return on Equity
7.34%
Trailing 12-Months
Asset Growth
-1.56%
Trailing 12-Months
Company Description
Sanofi
Sanofi (SNY) is a global healthcare company headquartered in Paris, France, engaged in the research, development, manufacturing, and marketing of pharmaceutical products. The company operates in several sectors, including specialty care, vaccines, and general medicines, with a focus on therapeutic areas such as oncology, immunology, rare diseases, multiple sclerosis, cardiovascular, diabetes, and consumer healthcare. Sanofi's core offerings include prescription medications, over-the-counter drugs, and vaccines aimed at improving the quality of life for patients worldwide.
---
SNY Company Deck
---
SNY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance in sales and strategic growth, especially in new product launches and the vaccines segment. However, there are concerns about increased expenses, slight gross margin decline, and impacts from healthcare policy changes. Despite these challenges, the company's growth outlook and pipeline advancements contribute to a generally positive sentiment.Read More>---
SNY Stock 12 Month Forecast
Average Price Target
$64.00
▲(20.71% Upside)
Technical Analysis
Best Analysts Covering SNY
1 Year
1 Year Success Rate
6/9 ratings generated profit
1 Year Average Return
+0.36%
reiterated a buy rating 2 months ago
Copying Luisa Hector's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +0.36% per trade.
---